A retrospective study: Can dual ART mitigate the risk of potential drug-drug interactions among PLWH under stable ART?
Turkish Journal of Medical Sciences · 26.10.2023 · 53 (5) · 1505-1511
DOI: 10.55730/1300-0144.5718 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 26.10.2023. Verfasst von Ahmet Çağkan Inkaya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkiye. Hauptthemen laut MEDLINE: Drug Interactions, HIV Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background/aim: People living with human immunodeficiency virus (PLWH) are getting older. Age-related comorbidities in PLWH result in polypharmacy and increase the risk for potential drug-drug interactions (pDDIs). This study aimed to evaluate how the rate of pDDIs would change if the treatment of patients receiving different combined antiretroviral therapies (ARTs) were theoretically changed with dolutegravir/lamivudine (DTG+3TC) or cabotegravir/rilpivirine (CAB+RPV). Materials and methods: This study was conducted at the infectious disease outpatient clinic of a university hospital as a follow-up of a previous study. The data of PLWH receiving at least 1 comedication other than antiretrovirals (ARVs) were retrospectively reviewed and analyzed. The Drugs.com/Drug Interactions Checker and University of Liverpool HIV Drug Interactions Checker databases were used to identify pDDIs and their severities.
Results
A total of 75 PLWH, of whom 83% were male, with a mean age (± standard deviation) of 46.5 (±12.98) years were included. Polypharmacy was observed in 59 (79%) of the participants; however, with dual ARV options, the probability of polypharmacy was 35 (47%) (p < 0.001). In the Drugs.com database, no significant difference was found in terms of pDDIs between the treatment of current ARTs (64%) and DTG/3TC (%44) (p = 0.06) or CAB/RPV (%64) (p = 0.521). However, in the University of Liverpool database, the current rate of pDDIs (55%) was significantly higher compared to the theoretical treatment of DTG/3TC (40%) (p = 0.029), oral CAB/ RPV (48%) (p = 0.003), and injectable CAB/RPV (31%) use (p = 0.006).
Conclusion
The results suggest that dual treatment regimens can reduce pDDIs, resulting in better tolerance and probably higher quality of life among PLWH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkiye.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Gazi University, Ankara, Turkiye.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkiye.
ORCID-Profile: Ahmet Çağkan Inkaya, Fatma Nisa Balli, Emre Kara, Kutay Demirkan, Serhat Ünal
Zitieren
APA
Inkaya, A. Ç., Balli, F. N., Kara, E., Demirkan, K., & Ünal, S. (2023). A retrospective study: Can dual ART mitigate the risk of potential drug-drug interactions among PLWH under stable ART?. Turkish Journal of Medical Sciences, 53(5), 1505-1511. https://doi.org/10.55730/1300-0144.5718
Vancouver
Inkaya AÇ, Balli FN, Kara E, Demirkan K, Ünal S. A retrospective study: Can dual ART mitigate the risk of potential drug-drug interactions among PLWH under stable ART?. Turkish Journal of Medical Sciences. 2023;53(5):1505-1511. doi:10.55730/1300-0144.5718
BibTeX
@article{Inkaya2023,
author = {Inkaya, Ahmet Çağkan and Balli, Fatma Nisa and Kara, Emre and Demirkan, Kutay and Ünal, Serhat},
title = {A retrospective study: Can dual ART mitigate the risk of potential drug-drug interactions among PLWH under stable ART?},
journal = {Turkish Journal of Medical Sciences},
year = {2023},
volume = {53},
number = {5},
pages = {1505--1511},
doi = {10.55730/1300-0144.5718}
}
EUVIMED